PFE Jun 2023 25.000 put
| Previous Close | 0.0200 |
| Open | 0.0200 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 25.00 |
| Expire Date | 2023-06-16 |
| Day's Range | 0.0200 - 0.0200 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
ZacksPfizer (PFE) Down 1.1% Since Last Earnings Report: Can It Rebound?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksBiohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates
At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.
- Reuters
UPDATE 2-Pfizer says its experimental antibiotic combo can treat some superbug infections
Pfizer Inc said on Thursday data from late-stage trials showed its experimental combination of antibiotics was effective in treating deadly infections caused by drug-resistant bacteria. Deaths from antibiotic-resistant bacteria, also known as superbugs, have been on the rise globally, and health regulators have called for the development of newer treatments as resistance to older antibiotics grows. The late-stage studies compared the experimental combination of the antibiotics aztreonam-avibactam (ATM-AVI) and existing generic drug metronidazole with a combination of two older antibiotics - meropenem and colistin - to treat complicated intra-abdominal infections and types of hospital-acquired pneumonia.
Business WirePhase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
NEW YORK, June 01, 2023--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combination aztreonam-avibactam (ATM-AVI) in treating serious bacterial infections due to Gram-negative bacteria, including metallo-β-lactamase (MBL)-producing multidrug-resistant pathogens for which there are limited or no treatme
Motley FoolHave $2,000? 2 Remarkable Growth Stocks to Buy Right Now
Regardless of your investing experience or risk tolerance, putting cash into stocks takes a certain tolerance for volatility and uncertainty. Investing in wonderful businesses, diversifying the ones you own, holding onto those great companies through the market's highs and lows, and avoiding traps like market timing can help you outpace the returns of the average retail investor through the years. Pfizer (NYSE: PFE) caught the attention of many investors when it became one of the leading contenders in the race to get a COVID-19 vaccine to market.
ZacksPfizer's (PFE) RSV Vaccine for Older Adults Gets FDA Approval
The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for older adults, making it the second RSV vaccine to be approved by the regulatory agency.
- Reuters
UPDATE 2-US FDA approves Pfizer's RSV vaccine
The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors. The approval comes less than a month after the FDA approved a similar shot by rival GSK Plc. Pfizer's vaccine was approved for people aged 60 and older, the company said, the same age group as GSK's shot. In a late-stage study, Pfizer's vaccine, to be sold under the brand name Abrysvo, was 67% effective among those aged 60 and older with two or more symptoms of RSV, and 85.7% against severe illness defined by three or more symptoms.
Business WireU.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
NEW YORK, May 31, 2023--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older. ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective.
Motley FoolWhy Pfizer Stock Is Perking Up Today
Shares of pharma titan Pfizer (NYSE: PFE) were up by 2.24% on moderate volume as of 2:29 p.m. ET Wednesday afternoon. Earlier Wednesday, The Wall Street Journal published a column questioning whether investors have turned too bearish on COVID-19 vaccine-makers like Pfizer. Pfizer's shares have fallen by as much as 30% this year in response to the anticipated drop in sales for its COVID-19 vaccine Comirnaty and antiviral treatment Paxlovid.
ZacksPfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study
Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.
Motley FoolDoes Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?
A highly lucrative weight-loss market could be the growth opportunity Pfizer needs to make the stock a better buy.
Motley Fool2 Ultra-Safe Dividend Stocks to Load Up On Right Now
Which top-shelf dividend stocks are worth buying right now? Allstate (NYSE: ALL) and Pfizer (NYSE: PFE) are two near-locks to produce healthy levels of capital appreciation over the next five to 10 years. Allstate's 2023 Q1 earnings report isn't exactly a confidence-inspiring read.
ZacksValneva (VALN) Stock Down 53% in the Past Year: Here's Why
The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.
ZacksPfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- Reuters
Pfizer's hemophilia therapy reduces bleeding in late-stage study
U.S. drugmaker Pfizer Inc said on Tuesday late-stage study data for its experimental hemophilia therapy showed superiority to the current standard of care treatment in reducing bleeding rates in patients. The therapy, marstacimab, met its main trial goal, demonstrating superiority to factor replacement therapies, with a 92% reduction in bleeding in patients with severe hemophilia A and moderately severe to severe hemophilia B, Pfizer said. Hemophilia hampers the body's ability to make blood-clotting proteins, leading to prolonged bleeding following injuries or surgery, and it primarily affects males, according to government data.
Business WirePfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
NEW YORK, May 30, 2023--Pfizer Inc. (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects. Marstacimab, a novel, investigational anti-tissue factor pathway inhibitor (anti-TFPI) being studied for the treatment of hemophilia A or B for people without inhibitors to Factor VIII (FVIII) or Factor IX (FIX), was administered weekly with fl
Motley FoolPfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?
The company also continues to benefit from sales of blockbusters including blood thinner Eliquis and oncology drug Ibrance. In fact, Pfizer expects patent losses alone to lead to $17 billion in lost revenue from 2025 through 2030. In spite of these upcoming obstacles, is Pfizer still a buy?
ZacksEMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval
Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.
Motley FoolThe Top Healthcare Stocks to Buy With $100
The healthcare industry is diverse and complex, with longtime staples and emerging disruptors to fit your portfolio -- and it also doesn't need to cost an arm and a leg. Here are several possibilities to consider, each playing a different role in the healthcare system. In an industry where size matters, Pfizer (NYSE: PFE) is one of the industry's most prominent players, with a market cap of over $200 billion.
Motley FoolInvesting $43 in This Stock per Week for 5 Years Could Give You $500 in Annual Dividend Income
If you're thinking of investing in Pfizer (NYSE: PFE) to generate some passive income from your portfolio, you won't need to spend very much to do so, provided that you're willing to play the long game. Building up a passive income stream is often a lot more manageable when you can do it piece by piece rather than paying out a large lump sum. Dollar-cost averaging (DCA) refers to buying a few shares of a stock here and there over a period of time so that you don't need a lump sum to reach your target position size.
Motley Fool3 No-Brainer Stocks to Buy for Under $100 Right Now
Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Novocure (NASDAQ: NVCR), and Pfizer (NYSE: PFE). David Jagielski (CRISPR Therapeutics): Shares of CRISPR Therapeutics are trading below $70, but it may not be long before they take off. The company has a promising gene-editing therapy in exa-cel for rare blood disorders beta-thalassemia and sickle cell disease that it has been working on with Vertex Pharmaceuticals.
- Zacks
Pfizer's (PFE) COVID-19 Oral Treatment Gets FDA Nod in Adults
Per the FDA, Pfizer's (PFE) Paxlovid is the first oral antiviral pill approved in the United States to treat COVID-19 in adults. The drug was granted emergency use authorization by the FDA in 2021.
Yahoo Finance VideoPfizer weight loss drug may be as effective as competitors: Study
Yahoo Finance Live health care reporter Anjalee Khemlani details the clinical trial results of Pfizer's weight loss drug Danuglipron, how it compares to Novo Nordisk's Ozempic, and examines the adoption of weight loss drugs in the health and wellness space.
- Reuters
UPDATE 2-EU, Pfizer/BioNTech announce amendment to COVID vaccine contract
The European Union and drugmakers Pfizer and BioNTech said on Friday they had reached a deal to amend a COVID-19 vaccine contract, cutting the number the EU must buy and pushing the delivery deadline to 2026. The agreement, first reported by Reuters earlier on Friday, comes after months of talks and amid pressure on Brussels from EU governments to secure a change to the contract because of a global glut of COVID-19 vaccine doses and low demand for boosters. The amended contract matches "evolving needs", said EU Health Commissioner Stella Kyriakides in a statement.
Motley FoolWhy Pfizer Stock Slipped by 2% Today
The market wasn't impressed by the company's latest drug approval, plus an analyst cut her price target on the shares.
